Engineering Allorejection-Resistant CAR-NKT Cells from Hematopoietic Stem Cells for Off-The-Shelf Cancer Immunotherapy.
Journal
Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581
Informations de publication
Date de publication:
06 Apr 2024
06 Apr 2024
Historique:
received:
31
12
2023
revised:
21
02
2024
accepted:
03
04
2024
medline:
8
4
2024
pubmed:
8
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
The clinical potential of current FDA-approved chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy is encumbered by its autologous nature, which presents notable challenges related to manufacturing complexities, heightened costs, and limitations in patient selection. Therefore, there is a growing demand for off-the-shelf universal cell therapies. In this study, we have generated universal CAR-engineered NKT (
Identifiants
pubmed: 38584391
pii: S1525-0016(24)00221-1
doi: 10.1016/j.ymthe.2024.04.005
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.